she continues to receive after 9 months on treatment. Notable adverse effects include transient grade 3 neutropenia without fever and not requiring growth factor support, and grade 1 thrombocytopenia without bleeding and not requiring transfusions
Search Results
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer
John A. Sharp, Daniel Jones, Julia K. Rotow, Panos M. Fidias, Erin Bertino, and Dwight H. Owen
Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
Presented by: William J. Gradishar
a 7% improvement in both invasive disease–free and distant relapse–free survival after 5 years of follow-up. Side effects differ between the 2 drugs, with ribociclib associated with more neutropenia and liver function test elevation, and
Updates in the Treatment of Metastatic Colorectal Cancer
Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh
representation was very limited; (3) PFS was significantly improved: 5.6 versus 2.4 months (HR, 0.44; 95% CI, 0.36–0.54); and (4) the safety profile was manageable, with neutropenia, nausea, and anemia being comparable or slightly higher in terms of any
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar
Grade 3/4 thrombocytopenia was higher with bosutinib and grade 3/4 neutropenia was higher with imatinib. Grade 3/4 anemia was similar in both groups. Discontinuation of therapy due to drug-related adverse events occurred in 14% of patients in the
Colon Cancer, Version 3.2014
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
diarrhea, dehydration, and severe neutropenia. 123 , 124 Irinotecan is inactivated by the enzyme uridine diphosphate glucuronosyl-transferase 1A1 (UGT1A1), which is also involved in converting substrates, such as bilirubin, into more soluble forms through
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson III, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer Jr., Robert A. Wolff, Brian M. Wolpin, Beth Lynn, and Giby V. George
FOLFIRINOX regimen. In the PRODIGE trial, some of the grade 3-4 toxicity rates that were significantly greater in the FOLFIRINOX group than in the gemcitabine group were 45.7% for neutropenia, 12.7% for diarrhea, 9.1% for thrombocytopenia, and 9.0% for
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
; febrile neutropenia rate was 4% versus 14%, and other toxicities and overall QOL were similar. Docetaxel is included as an upfront option for men with castration-naïve prostate cancer and distant metastases based on results from 2 phase 3 trials (ECOG 3805
Management of Patients With Lung Cancer and Poor Performance Status
Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti
, toxicity, especially myelosuppression and esophagitis, is higher with concurrent chemotherapy and radiation. Patients with poor PS are likely to have more chemotherapy-related complications secondary to myelosuppression, especially anemia and neutropenia. 5
Developments in Molecular Testing and Biosimilars
Katy Winckworth-Prejsnar, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C. Lyn Fitzgerald, and Robert W. Carlson
-CSF). It is approved for all indications of filgrastim to treat patients with (1) nonmyeloid malignancy receiving myelosuppressive chemotherapy with an intermediate- or high-risk of febrile neutropenia; (2) acute myeloid leukemia receiving induction or
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017
Patrick A. Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K. Barta, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Ryan Cassaday, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Olga Frankfurt, John P. Greer, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L. Uy, Eunice S. Wang, Kristina M. Gregory, and Ndiya Ogba
%; median OS, 7.5 weeks; early induction death, 30%). 73 , 74 The most common grade ≥3 treatment-related toxicities with VSLI included neuropathy (23%), neutropenia (15%), and thrombocytopenia (6%). 73 Based on phase II data from the RALLY study, VSLI was
